# Pelthos Posts $2.04 GAAP Loss Per Share as Zelsuvmi Revenue Rises 114% By John Kim Canonical URL: https://www.tokenpost.com/news/business/55688 Published: 2026-11-12T17:19:31.000Z Updated: 2026-11-12T17:19:31.000Z Section: Business > Total revenue reached $15.4 million, and the net loss narrowed to $7.9 million from $16.2 million a year earlier. Pelthos Therapeutics Inc. posted a $2.04 GAAP loss per share in the third quarter of 2026, while net product revenue from its lead product, Zelsuvmi, rose 114% from a year earlier. Zelsuvmi generated $15.2 million in net product revenue, compared with $7.1 million in the third quarter of 2025. Net product revenue declined 1% from the second quarter of 2026. Pelthos recorded total revenue of $15.4 million for the quarter. Its net loss narrowed to $7.9 million from $16.2 million a year earlier. The results follow Pelthos’ [October merger agreement with Castle Creek Biosciences](). Pelthos expects the merger to close by the end of March 2027, pending approval from Castle Creek stockholders and satisfaction of other customary conditions. ## Links in this article - [October merger agreement with Castle Creek Biosciences](https://www.tokenpost.com/news/business/44881)